Abstract
Background Patients with ischemic stroke and active cancer have a poor prognosis; however, supporting evidence remains limited.
Methods We conducted a prospective, multicenter, observational study in Japan including patients with acute ischemic stroke and active cancer to investigate the prognostic factors. We followed up the patients for 1 year after stroke onset. The patients were divided into two groups according to cryptogenic stroke and known etiologies (small vessel occlusion, large artery atherosclerosis, cardioembolism, other determined etiology) and survival was compared. The hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality were calculated using Cox regression models.
Results We identified 135 eligible patients (39% women; median age, 75 years). Of these, 51% had distant metastasis. A total of 65 (48%) and 70 (52%) patients had cryptogenic stroke and known etiologies, respectively. Patients with cryptogenic stroke had significantly shorter survival than those with known etiologies (HR [95% CI], 3.11 [1.82–5.25]). The multivariate Cox regression analysis revealed that distant metastasis, plasma D-dimer levels, deep venous thrombosis and/or pulmonary embolism complications at stroke onset were independent predictors of mortality after adjusting for potential confounders. Cryptogenic stroke was associated with prognosis in univariate analysis but not significant in multivariate analysis. The plasma D-dimer levels stratified the prognosis of patients with ischemic stroke and active cancer.
Conclusions The prognosis of patients with acute ischemic stroke and active cancer varies considerably depending on stroke mechanism, distant metastasis, and coagulation abnormalities. Coagulation abnormalities are crucial in determining the prognosis of such patients.
We conducted a prospective, multicenter, observational study in Japan to determine the prognostic survival factors in patients with acute ischemic stroke and active cancer.
Distant metastasis, plasma D-dimer levels, deep venous thrombosis and/or pulmonary embolism were independent predictors of mortality after adjusting for potential confounders.
Patients with known stroke etiologies and mild coagulation abnormalities had a favorable prognosis, whereas those with cryptogenic stroke and severe coagulation abnormalities had a poor outcome.
The prognosis of patients with acute ischemic stroke and active cancer varies considerably depending on stroke mechanism, distant metastasis, and coagulation abnormalities.
Patients with known stroke etiologies and mild coagulation abnormalities often have a favorable prognosis; therefore, we should not stop stroke therapy because of active cancer.
Patients with cryptogenic stroke and severe coagulation abnormalities often have poor outcomes; consequently, we should thoroughly discuss with the oncologist to determine a treatment plan.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by JSPS KAKENHI [grant Number: JP15K08915].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complied with the Declaration of Helsinki for investigations involving humans and was approved by the Institutional Review Board of Osaka University Hospital (approval number: 15346-10). Written informed consent was obtained from all study patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available on reasonable request to the corresponding author.
Non-standard Abbreviations and Acronyms
- HR
- Hazard ratio
- CI
- Confidence interval
- SCAN
- Ischemic Stroke in Patients with Cancer and Neoplasia
- NIHSS
- National Institute of Health Stroke Scale
- DVT
- Deep venous thrombosis
- PE
- Pulmonary embolism
- mRS
- modified Rankin Scale
- rt-PA
- Recombinant-tissue plasminogen activator
- hsCRP
- High-sensitivity C-reactive protein
- TOAST
- Trial of Org 10172 in Acute Stroke Treatment
- IQR
- Interquartile range
- AIC
- Akaike’s information criterion
